Single-cell research opens doors to new areas of discovery. Illumina’s acquisition of Fluent BioSciences Inc. and its innovative, accessible, and flexible single-cell method allows us to address new use cases and accelerates our drive toward full multiomics solutions for our customers. I’m pleased to welcome our new colleagues and look forward to working together to expand Illumina’s multiomics portfolio.
Today Illumina is acquiring Fluent BioSciences Inc. to accelerate the adoption of single-cell analysis and help customers with the broadest range of project sizes. On our mission to unlock the power of the genome to improve human health, we see this as a step to enable faster discovery. Learn more: https://bit.ly/3XYQdPk
Kyle Giffin
2w
Congratulations on the acquisition, Steven. Phenomenal team and technology, with a clear vision for where single-cell is going. We hope to see continued growth for both of you.
Life Sciences Executive, Start-up Co-Founder, R&D leader
2wThrilled to be joining the Illumina team!